Novartis’ breast cancer drug LEEO11 gains breakthrough status
breast cancer, LEE011, Novartis
0 Comment
Drug will challenge Pfizer’s Ibrance
LEE011
breast cancer, LEE011, Novartis
0 Comment
Drug will challenge Pfizer’s Ibrance